Table 2

Laboratory, clinical and imaging findings of the 10 study patients with brucellar spondylitis at the end of treatment
Pt Duration of treatment (months) Findings at the end of treatment Duration of follow-up after treatment discontinuation (months)
ESR mm/hr CRP mg/L SAT titers WBC K/μl Clinical MRI residual findings F-18 FDG PET/CT findings F-18 FDG PET/CT SUVmax
1 12 40 5.00 1/320 4.70 (−) L5 – S1 L2 – L3, L5 – S1 3.2 2.6 27
2 12 10 5.00 1/680 6.50 (−) T7 – T8 T7 – T8, L4 – L5 3.3 2.0 13
3 9 5 3.08 1/ 10240 4.43 (−) L2 – L3 L3 2.9 21
4 12 35 10.00 1/320 6.65 (−) L4 – L5 L5 T6 2.6 2.9 10
5 6 15 2.97 < 1/160 7.24 (−) (−) (−) 0 9
6 11 15 2.97 1/320 5.15 Back pain on effort L4 – L5 L4 – L5 2.7 8
7 12 17 3.08 < 1/160 7.85 Pain on weather changes (−) T7 2.0 17
8 12 20 4.10 < 1/160 8.90 (−) (−) L3 2.0 11
9 6 14 5.00 < 1/160 7.70 (−) (−) L3 3.0 21
10 12 23 5.00 < 1/160 4.80 Back pain on effort L4 – L5 L1 – L2, L4 – L5 2.9 4.4 12

NOTES. Pt: patient number, ESR: erythrocyte sedimentation rate (normal value, 40 mm/hour), CRP: C-reactive protein (normal values < 5 mg/L), WBC: white blood count, SAT: slide agglutination test (normal values < 1/160), MRI: magnetic resonance imaging, F-18 FDG PET/CT: fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography combined with computed tomography scan, SUVmax: maximum standard uptake value.

Ioannou et al.

Ioannou et al. BMC Infectious Diseases 2013 13:73   doi:10.1186/1471-2334-13-73

Open Data